Nippon Kayaku Co., Ltd.
【Nihon Kagaku Pharmaceutical】Share Buyback of 286,900 shares (~¥6.16 billion)｜May 2026
Nihon Kagaku Pharmaceutical resolved at its Board of Directors meeting on May 12, 2026, to acquire 286,900 shares of treasury stock through market purchases on the Tokyo Stock Exchange, at a total cost of approximately ¥6.16 billion. The acquisition period is from May 13 to May 31, 2026.
Key Figures
- Total shares acquired: 286,900 shares
- Total acquisition cost: ¥616,642,500
- Acquisition period: May 13, 2026 – May 31, 2026
AI要約
Overview of Capital Policy
Nihon Kagaku Pharmaceutical, following a resolution at its Board of Directors meeting on May 12, 2026, acquired 286,900 shares of treasury stock through market purchases, investing approximately ¥6.16 billion. The acquisition period is from May 13 to May 31, 2026, with a maximum limit of 13,000,000 shares and a total budget of ¥1.5 billion. This buyback is part of their shareholder return strategy, aimed at preventing shareholder dilution and enhancing shareholder value.
Impact on Shareholders and Future Outlook
Following this share buyback, the proportion of treasury stock to total issued shares will be 8.75%. The company intends to continue considering acquisitions of shares and dividend policies as part of its capital management, aiming to improve shareholder value. The acquired shares will be circulated in the market to ensure liquidity and strengthen shareholder returns.
Nihon Kagaku Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
